BR112014010664A2 - uso de um anticorpo anti-alfa-sinucleína para diagnosticar um nível elevado de alfa-sinucleína no cérebro - Google Patents

uso de um anticorpo anti-alfa-sinucleína para diagnosticar um nível elevado de alfa-sinucleína no cérebro

Info

Publication number
BR112014010664A2
BR112014010664A2 BR112014010664A BR112014010664A BR112014010664A2 BR 112014010664 A2 BR112014010664 A2 BR 112014010664A2 BR 112014010664 A BR112014010664 A BR 112014010664A BR 112014010664 A BR112014010664 A BR 112014010664A BR 112014010664 A2 BR112014010664 A2 BR 112014010664A2
Authority
BR
Brazil
Prior art keywords
synuclein
brain
diagnose
antibody
high level
Prior art date
Application number
BR112014010664A
Other languages
English (en)
Inventor
Weihofen Andreas
Grimm Jan
Engber Thomas
Original Assignee
Biogen Idec Int Neuroscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Int Neuroscience Gmbh filed Critical Biogen Idec Int Neuroscience Gmbh
Publication of BR112014010664A2 publication Critical patent/BR112014010664A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

abstract this disclosure relates to the use of anti-a-synuclein antibody to diagnose an elevated level of a-synuclein in the brain. specifically, the disclosure relates to the method of assessing the levels of a-synuclein in a blood plasma or csf following administration to the test subject of an anti-a-synuclein antibody or antigen-binding fragment thereof, which can bind a-synuclein with sufficient activity to alter the net efflux of a-synuclein from brain to blood, or from brain to csf. tradução do resumo resumo patente de invenção: "uso de um anticorpo anti-alfa-sinucleína para diagnosticar um nível elevado de alfa-sinucleína no cérebro". esta divulgação refere-se ao uso do anticorpo anti-a-sinucleína para diagnosticar um nível elevado de a-sinucleína no cérebro. especificamente, a divulgação refere-se ao método de avaliação dos níveis de a-sinucleína no plasma sanguíneo ou no lcr após a administração ao sujeito de teste de um anticorpo anti-a-sinucleína ou de seu fragmento de ligação ao antígeno, que pode ligar a a-sinucleína com atividade suficiente para alterar o efluxo líquido da a-sinucleína do cérebro para o sangue, ou do cérebro para o lcr.
BR112014010664A 2011-11-02 2012-10-29 uso de um anticorpo anti-alfa-sinucleína para diagnosticar um nível elevado de alfa-sinucleína no cérebro BR112014010664A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161554924P 2011-11-02 2011-11-02
PCT/US2012/062430 WO2013066818A1 (en) 2011-11-02 2012-10-29 USE OF AN ANTI-α-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL OF α-SYNUCLEIN IN THE BRAIN

Publications (1)

Publication Number Publication Date
BR112014010664A2 true BR112014010664A2 (pt) 2017-04-25

Family

ID=48192661

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010664A BR112014010664A2 (pt) 2011-11-02 2012-10-29 uso de um anticorpo anti-alfa-sinucleína para diagnosticar um nível elevado de alfa-sinucleína no cérebro

Country Status (14)

Country Link
US (3) US20140295465A1 (pt)
EP (1) EP2773957B1 (pt)
JP (1) JP6263473B2 (pt)
KR (1) KR102036938B1 (pt)
CN (2) CN107091931A (pt)
AU (1) AU2012332814B2 (pt)
BR (1) BR112014010664A2 (pt)
CA (1) CA2854131C (pt)
EA (1) EA034213B1 (pt)
HK (1) HK1201585A1 (pt)
IL (1) IL232373B (pt)
MX (1) MX356797B (pt)
WO (1) WO2013066818A1 (pt)
ZA (1) ZA201403879B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2949666T1 (sl) 2008-12-19 2019-03-29 Biogen International Neuroscience Gmbh Človeška anti alfa-sinukleinska protitelesa
LT2723379T (lt) 2011-06-23 2018-10-25 Biogen International Neuroscience Gmbh Anti-alfa sinukleiną rišančios molekulės
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
JP6273338B1 (ja) * 2016-12-05 2018-01-31 磁量生技股▲ふん▼有限公司 パーキンソン病からパーキンソン病認知症を特定する方法
MX2019008029A (es) * 2017-01-06 2019-12-11 Abl Bio Inc Anticuerpo anti-alfa-sinucleina y su uso.
CA3049110A1 (en) * 2017-01-06 2018-07-12 Abl Bio Inc. Anti-.alpha.-syn antibody and use thereof
KR102573778B1 (ko) 2017-02-17 2023-08-31 브리스톨-마이어스 스큅 컴퍼니 알파-시뉴클레인에 대한 항체 및 그의 용도
GB201803553D0 (en) 2018-03-06 2018-04-18 Univ Newcastle Detection of pathological protein aggregation
WO2020009482A1 (ko) * 2018-07-03 2020-01-09 에이비엘바이오 주식회사 항 알파-시누클레인 항체 및 그 용도
EP3629021A1 (en) * 2018-09-26 2020-04-01 Euroimmun Medizinische Labordiagnostika AG Diagnosis of a neuroautoimmune disease
KR102252879B1 (ko) * 2019-11-15 2021-05-17 성균관대학교산학협력단 혈장 내 aimp2를 이용한 파킨슨 질환의 진단 방법, 이를 위한 조성물 및 이를 포함하는 키트

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
AU3117799A (en) * 1998-03-30 1999-10-18 Trustees Of The University Of Pennsylvania, The Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders
CN1440420A (zh) * 2000-07-07 2003-09-03 万能药制药公司 预防神经组织损伤和治疗α－共核蛋白疾病的方法
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
CA2657953A1 (en) * 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
EP3239175A1 (en) 2007-01-05 2017-11-01 University of Zurich Method of providing disease-specific binding molecules and targets
CN101308144A (zh) * 2007-05-16 2008-11-19 首都医科大学宣武医院 检测受试者体液内疾病相关蛋白聚合能力的方法
DK2282758T3 (en) * 2008-04-29 2019-02-25 Bioarctic Ab ANTIBODIES AND VACCINES FOR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR ALPHA-SYNUCLEIN-RELATED DISORDERS
SI2949666T1 (sl) * 2008-12-19 2019-03-29 Biogen International Neuroscience Gmbh Človeška anti alfa-sinukleinska protitelesa
CN101692092B (zh) * 2009-09-24 2013-04-10 首都医科大学宣武医院 定量检测人血清中自体α-突触核蛋白抗体的方法

Also Published As

Publication number Publication date
CA2854131A1 (en) 2013-05-10
ZA201403879B (en) 2018-11-28
MX356797B (es) 2018-06-14
US20140295465A1 (en) 2014-10-02
US20180011112A1 (en) 2018-01-11
JP6263473B2 (ja) 2018-01-31
AU2012332814A1 (en) 2014-06-12
CN104040342A (zh) 2014-09-10
EA201490883A1 (ru) 2014-10-30
EP2773957A4 (en) 2015-06-24
EA034213B1 (ru) 2020-01-17
IL232373A0 (en) 2014-06-30
EP2773957A1 (en) 2014-09-10
CA2854131C (en) 2020-07-07
IL232373B (en) 2018-08-30
NZ625217A (en) 2016-07-29
US20190094245A1 (en) 2019-03-28
HK1201585A1 (en) 2015-09-04
JP2014533357A (ja) 2014-12-11
CN107091931A (zh) 2017-08-25
KR102036938B1 (ko) 2019-10-25
KR20140095074A (ko) 2014-07-31
WO2013066818A1 (en) 2013-05-10
AU2012332814B2 (en) 2017-12-14
MX2014005378A (es) 2015-01-19
EP2773957B1 (en) 2017-11-29

Similar Documents

Publication Publication Date Title
BR112014010664A2 (pt) uso de um anticorpo anti-alfa-sinucleína para diagnosticar um nível elevado de alfa-sinucleína no cérebro
ECSP16060104A (es) Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este
BR112018074978A2 (pt) anticorpos para alfa-sinucleína e usos dos mesmos
BR112013023540A2 (pt) anticorpo, kit e método para a determinação de peptídeos amilóides
BR112017028353A2 (pt) anticorpos para cd40 com atividade agonista melhorada
BR112013028779B8 (pt) proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, e, uso de uma composição
BR112012007365A2 (pt) proteínas de ligação à il-1
CY1116584T1 (el) Ανθρωπινα αυτοαντισωματα αντι-αλφα-συνουκλεϊνης
CL2007000478A1 (es) Anticuerpo humano o humanizado o fragmento funcional del mismo especifico para linfopoyetina estromal timica, tslp; polinucleotido que lo codifica; celula huesped que lo comprende; composicion farmaceutica que comprende al anticuerpo; y metodo para t
AR071656A1 (es) Moleculas de union al antigeno que se unen repetidamente a multiples moleculas de antigeno
WO2011142827A3 (en) Diagnostic markers for neuropsychiatric disease
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
BRPI0914925A2 (pt) peptídeo cíclico, uso de um peptídeo, métodos para produzir um peptídeo cíclico e para diagnosticar uma doença ou condição, e, anticorpo
BR112013021350A2 (pt) anticorpo e antígeno reconhecido de células iniciadoras de tumor e o uso destes
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
JP2014533357A5 (pt)
BRPI0706575B8 (pt) uso colágeno de tipo v ou um componente antigênico do mesmo, e, método para identificar um paciente em espera de transplante de pulmão para um risco aumentado de rejeição de tecido de órgão transplantado.
WO2011100396A3 (en) Serum clusterin levels in systemic amyloidosis featuring cardiomyopathy
BR112013015817A2 (pt) sistema de ultrassom diagnóstico para medir o fluxo regurgitante e método para avaliar fluxo regurgitante com um sistema de ultrassom
BR112014031958A2 (pt) bag3 como marcador de tecido e soro bioquímico
DK3759469T3 (da) In-line test med udvikling til diagnostisk analyse
EA201491411A1 (ru) Растворимый manf при поражениях бета-клеток поджелудочной железы
JP2014517308A5 (pt)
EA201400571A1 (ru) Специфичные к трансресвератролу антитела и их применение
EA201490576A1 (ru) Молекулярный маркер для ранней диагностики мезотелиомы плевры у пациентов и способы для анализа его экспрессии

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BIOGEN INTERNATIONAL NEUROSCIENCE GMBH (CH)

B25G Requested change of headquarter approved

Owner name: BIOGEN INTERNATIONAL NEUROSCIENCE GMBH (CH)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B25G Requested change of headquarter approved

Owner name: BIOGEN INTERNATIONAL NEUROSCIENCE GMBH (CH)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

B350 Update of information on the portal [chapter 15.35 patent gazette]